Multicenter Study for External Validation of the TB-NET Score (TB-NET)
Multicentric Study for External Validation of the TB-NET Score
This is a retrospective, observational, multicenter study aiming to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or lung carcinoids. The primary objective is to validate the prognostic value of the TB-NET Score for progression-free survival (PFS). Secondary objectives include the evaluation of overall survival (OS), objective response rate (ORR), grade 3-4 adverse events, biochemical and functional imaging correlates, and the potential additional prognostic value of tumor growth rate (TGR).
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a retrospective, observational, multicenter study designed to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated neuroendocrine tumors.
Eligible patients will include adults with histologically confirmed advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or typical or atypical lung carcinoids who have received systemic therapy. GEP-NETs may be grade 1, 2, or 3, provided that well-differentiated morphology is confirmed. Patients with poorly differentiated neuroendocrine carcinomas will be excluded.
The primary objective is to externally validate the prognostic value of the TB-NET Score for progression-free survival (PFS). Secondary objectives include the assessment of overall survival (OS), objective response rate (ORR), grade 3-4 adverse events, biochemical and functional imaging correlates, and evaluation of whether tumor growth rate (TGR) provides additional prognostic information for PFS.
A minimum of 200 patients is planned, with no predefined maximum sample size. Clinical, pathological, radiological, treatment, and outcome data will be retrospectively collected by participating centers and entered into a centrally coordinated electronic data capture system. Statistical analyses will be performed centrally by the Gastrointestinal Tumors Unit at Fundación Jiménez Díaz.
Only pseudonymized data will be shared for the purposes of the study. Data transfers between participating centers and the Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD) will be governed by appropriate data transfer agreements when required. The study has received approval from the Research Ethics Committee of Fundación Jiménez Díaz.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Angela Lamarca, MD, PhD
- Telefonnummer: 3146 +34 915504800
- E-post: angela.lamarca@quironsalud.es
Studera Kontakt Backup
- Namn: Diego Fernández, MD
- Telefonnummer: +34 636284882
- E-post: diego.fernandezr@quironsalud.es
Studieorter
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 01308-050
- Rekrytering
- Hospital Sírio-Libanês
-
Kontakt:
- Regis Franca, MD
- Telefonnummer: +55 11 3394-0200
- E-post: regisfranca@gmail.com
-
-
-
-
-
Clichy, Frankrike, 92110
- Rekrytering
- Hôpital Beaujon
-
Kontakt:
- Maxime Ronot, MD, PhD
- Telefonnummer: +33 1 40 87 50 00
- E-post: maxime.ronot@gmail.com
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Rekrytering
- Dana-Farber Cancer Institute
-
Kontakt:
- Jennifer Chan, MD
- Telefonnummer: 617-632-3000
- E-post: jennifer_chan@dfci.harvard.edu
-
-
-
-
Lombardy
-
Milan, Lombardy, Italien, 20132
- Rekrytering
- IRCCS Ospedale San Raffaele
-
Kontakt:
- Massimo Falconi, MD
- Telefonnummer: +39 02 26431
- E-post: falconi.massimo@hsr.it
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-688
- Rekrytering
- University Hospital in Kraków
-
Kontakt:
- Marta Opalinska, MD, PhD
- Telefonnummer: +48 12 400 10 00
- E-post: mkal@vp.pl
-
-
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Rekrytering
- Hospital Universitario Marqués de Valdecilla
-
Kontakt:
- Carlos Lopez, MD
- E-post: clopez@humv.es
-
-
Madrid
-
Madrid, Madrid, Spanien, 28040
- Rekrytering
- Hospital Universitario Fundación Jiménez Díaz
-
Kontakt:
- Diego Fernández, MD
- Telefonnummer: +34 636284882
- E-post: diego.fernandezr@quironsalud.es
-
-
-
-
Skåne County
-
Malmö, Skåne County, Sverige, 214 28
- Rekrytering
- Skåne University Hospital
-
Kontakt:
- Carl Fredrik Warfvinge, MD
- Telefonnummer: +46 40331000
- E-post: carl_fredrik.warfvinge@med.lu.se
-
-
-
-
Ankara
-
Ankara, Ankara, Turkiet (Türkiye), 06080
- Rekrytering
- Hacettepe University Hospitals
-
Kontakt:
- Murat Tuncel, MD
- Telefonnummer: +90 3123055000
- E-post: murat.tuncel@hacettepe.edu.tr
-
-
-
-
Bavaria
-
Erlangen, Bavaria, Tyskland, 91054
- Rekrytering
- Universitätsklinikum Erlangen
-
Kontakt:
- Marianne Pavel, MD
- Telefonnummer: +49 9131 85-0
- E-post: marianne.pavel@uk-erlangen.de
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.
Beskrivning
Inclusion Criteria:
- Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.
- Grade 1, 2 or 3 if well-differentiated morphology for GEP-NETs. Typical or Atypical Lung Carcinoids.
- At least one target lesion.
Exclusion Criteria:
- Patients with Neuroendocrine Carcinomas.
- Patients with no target lesions (according to RECIST 1.1 criteria).
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: RETROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Patients With Advanced Well-Differentiated NETs
Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsram: From treatment initiation until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 120 months.
|
Progression-free survival, defined as the time from treatment initiation to documented disease progression. Patients without documented progression at the end of follow-up will be censored at the date of the last follow-up without progression. |
From treatment initiation until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 120 months.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective Response Rate (ORR)
Tidsram: From treatment initiation until disease progression or the last tumor response assessment, assessed up to 120 months.
|
Response rate defined by RECIST 1.1 |
From treatment initiation until disease progression or the last tumor response assessment, assessed up to 120 months.
|
|
Overall Survival (OS)
Tidsram: From treatment initiation until death from any cause or last follow-up, assessed up to 120 months.
|
The time from treatment initiation to death; patients alive at the end of follow up will be censored at the time of last follow up. |
From treatment initiation until death from any cause or last follow-up, assessed up to 120 months.
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of Grade 3-4 Adverse Events According to CTCAE
Tidsram: From treatment initiation until treatment discontinuation or the last available safety assessment, assessed up to 120 months.
|
The proportion of patients experiencing at least one Grade 3 or 4 adverse event during treatment, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 adverse events are defined as severe, and Grade 4 adverse events as life-threatening. |
From treatment initiation until treatment discontinuation or the last available safety assessment, assessed up to 120 months.
|
|
Correlation of Chromogranin A, 5-HIAA, and Neuron-Specific Enolase Levels With TB-NET Score
Tidsram: At baseline, prior to treatment initiation.
|
The association between baseline biochemical marker levels, including chromogranin A (CgA), 5-hydroxyindoleacetic acid (5-HIAA), and neuron-specific enolase (NSE), and tumor burden assessed using the TB-NET Score will be evaluated. Correlations will be analyzed separately for each biomarker using appropriate statistical methods. |
At baseline, prior to treatment initiation.
|
|
Percentage of Patients With Positive Baseline 18F-FDG PET/CT According to TB-NET Score Risk Group
Tidsram: At baseline, prior to treatment initiation.
|
The percentage of patients with positive baseline fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) will be calculated separately for the low-risk (TB-NET Score 1-2) and high-risk (TB-NET Score ≥3) groups. Imaging positivity will be assessed as a binary variable (positive versus negative) based on the imaging report. Only patients with available baseline 18F-FDG PET/CT results will be included. Unit of Measure: Percentage of patients. |
At baseline, prior to treatment initiation.
|
|
Incremental Prognostic Value of Tumor Growth Rate at 3 and 6 Months for Progression-Free Survival
Tidsram: TGR assessed at 3 and 6 months after treatment initiation; subsequent PFS assessed from each landmark until disease progression or death from any cause, whichever occurs first, up to 120 months after treatment initiation.
|
The incremental prognostic value of tumor growth rate (TGR), assessed at 3 and 6 months after treatment initiation, will be evaluated for progression-free survival (PFS). TGR will be calculated using serial radiological tumor measurements and expressed as percentage tumor growth per month. Separate landmark analyses at 3 and 6 months will assess the association between TGR and subsequent PFS using Cox proportional hazards regression models, comparing the TB-NET Score alone with the TB-NET Score plus TGR. |
TGR assessed at 3 and 6 months after treatment initiation; subsequent PFS assessed from each landmark until disease progression or death from any cause, whichever occurs first, up to 120 months after treatment initiation.
|
|
Percentage of Patients With Positive Baseline 68Ga-SSTR PET/CT According to TB-NET Score Risk Group
Tidsram: At baseline, prior to treatment initiation.
|
The percentage of patients with positive baseline gallium-68-labeled somatostatin receptor positron emission tomography/computed tomography (68Ga-SSTR PET/CT) will be calculated separately for the low-risk (TB-NET Score 1-2) and high-risk (TB-NET Score ≥3) groups. Imaging positivity will be assessed as a binary variable (positive versus negative) based on the imaging report. Only patients with available baseline 68Ga-SSTR PET/CT results will be included. Unit of Measure: Percentage of patients. |
At baseline, prior to treatment initiation.
|
|
Percentage of Patients With Positive Baseline Somatostatin Receptor Scintigraphy According to TB-NET Score Risk Group
Tidsram: At baseline, prior to treatment initiation.
|
The percentage of patients with positive baseline somatostatin receptor scintigraphy (OctreoScan) will be calculated separately for the low-risk (TB-NET Score 1-2) and high-risk (TB-NET Score ≥3) groups. Imaging positivity will be assessed as a binary variable (positive versus negative) based on the imaging report. Only patients with available baseline OctreoScan results will be included. Unit of Measure: Percentage of patients. |
At baseline, prior to treatment initiation.
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Angela Lamarca, MD, PhD, Hospital Universitario Fundación Jiménez Díaz
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- EO016-26_FJD
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .